#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The rapid development of large-scale pharmaceutical manufacturing has contributed to increased concentrations of contaminants present in wastewater and surface waters .
2-1	16-19	The	event[2]	new[2]	_	_
2-2	20-25	rapid	event[2]	new[2]	_	_
2-3	26-37	development	event[2]	new[2]	_	_
2-4	38-40	of	event[2]	new[2]	_	_
2-5	41-52	large-scale	event[2]|abstract[3]	new[2]|new[3]	coref	3-8[0_3]
2-6	53-67	pharmaceutical	event[2]|abstract[3]	new[2]|new[3]	_	_
2-7	68-81	manufacturing	event[2]|abstract[3]	new[2]|new[3]	_	_
2-8	82-85	has	_	_	_	_
2-9	86-97	contributed	_	_	_	_
2-10	98-100	to	_	_	_	_
2-11	101-110	increased	animal[4]	new[4]	_	_
2-12	111-125	concentrations	animal[4]	new[4]	_	_
2-13	126-128	of	animal[4]	new[4]	_	_
2-14	129-141	contaminants	animal[4]|object	new[4]|new	_	_
2-15	142-149	present	animal[4]	new[4]	_	_
2-16	150-152	in	animal[4]	new[4]	_	_
2-17	153-163	wastewater	animal[4]|substance|substance[7]	new[4]|new|new[7]	coref|coref	5-19|10-18[73_7]
2-18	164-167	and	animal[4]|substance[7]	new[4]|new[7]	_	_
2-19	168-175	surface	animal[4]|substance[7]|substance[8]	new[4]|new[7]|new[8]	_	_
2-20	176-182	waters	animal[4]|substance[7]|substance[8]	new[4]|new[7]|new[8]	_	_
2-21	183-184	.	_	_	_	_

#Text=Pharmaceutical wastewaters are produced during the drug manufacturing processes ( i. e. , fermentation , extraction , chemical synthesis , formulation , packaging and washing of solid cake and equipment ) .
3-1	185-199	Pharmaceutical	substance[9]	new[9]	_	_
3-2	200-211	wastewaters	substance[9]	new[9]	_	_
3-3	212-215	are	_	_	_	_
3-4	216-224	produced	_	_	_	_
3-5	225-231	during	_	_	_	_
3-6	232-235	the	abstract[11]	new[11]	appos	3-16[0_11]
3-7	236-240	drug	abstract[11]	new[11]	_	_
3-8	241-254	manufacturing	abstract|abstract[11]	giv|new[11]	coref	6-4[38_0]
3-9	255-264	processes	abstract[11]	new[11]	_	_
3-10	265-266	(	_	_	_	_
3-11	267-269	i.	_	_	_	_
3-12	270-272	e.	_	_	_	_
3-13	273-274	,	_	_	_	_
3-14	275-287	fermentation	substance	new	_	_
3-15	288-289	,	_	_	_	_
3-16	290-300	extraction	abstract	giv	appos	3-18[14_0]
3-17	301-302	,	_	_	_	_
3-18	303-311	chemical	abstract[14]	giv[14]	appos	3-21[0_14]
3-19	312-321	synthesis	abstract[14]	giv[14]	_	_
3-20	322-323	,	_	_	_	_
3-21	324-335	formulation	substance	giv	appos	3-23
3-22	336-337	,	_	_	_	_
3-23	338-347	packaging	abstract	giv	appos	3-25[17_0]
3-24	348-351	and	_	_	_	_
3-25	352-359	washing	abstract[17]	giv[17]	coref	15-14[104_17]
3-26	360-362	of	abstract[17]	giv[17]	_	_
3-27	363-368	solid	abstract[17]|object[18]	giv[17]|new[18]	_	_
3-28	369-373	cake	abstract[17]|object[18]	giv[17]|new[18]	_	_
3-29	374-377	and	abstract[17]	giv[17]	_	_
3-30	378-387	equipment	abstract[17]|object	giv[17]|new	_	_
3-31	388-389	)	_	_	_	_
3-32	390-391	.	_	_	_	_

#Text=Hence , the main pollution source of these pharmaceutical compounds in the environment is through industrial process water discharge .
4-1	392-397	Hence	abstract[23]|abstract[25]	new[23]|giv[25]	coref	13-12[0_23]
4-2	398-399	,	abstract[23]|abstract[25]	new[23]|giv[25]	_	_
4-3	400-403	the	abstract[23]|abstract[25]	new[23]|giv[25]	_	_
4-4	404-408	main	abstract[23]|abstract[25]	new[23]|giv[25]	_	_
4-5	409-418	pollution	abstract|abstract[23]|abstract[25]	new|new[23]|giv[25]	_	_
4-6	419-425	source	abstract[23]|abstract[25]	new[23]|giv[25]	_	_
4-7	426-428	of	abstract[23]|abstract[25]	new[23]|giv[25]	_	_
4-8	429-434	these	substance[21]|abstract[23]|abstract[25]	new[21]|new[23]|giv[25]	_	_
4-9	435-449	pharmaceutical	substance[21]|abstract[23]|abstract[25]	new[21]|new[23]|giv[25]	_	_
4-10	450-459	compounds	substance[21]|abstract[23]|abstract[25]	new[21]|new[23]|giv[25]	_	_
4-11	460-462	in	substance[21]|abstract[23]|abstract[25]	new[21]|new[23]|giv[25]	_	_
4-12	463-466	the	substance[21]|abstract[22]|abstract[23]|abstract[25]	new[21]|new[22]|new[23]|giv[25]	_	_
4-13	467-478	environment	substance[21]|abstract[22]|abstract[23]|abstract[25]	new[21]|new[22]|new[23]|giv[25]	_	_
4-14	479-481	is	abstract[23]|abstract[25]	new[23]|giv[25]	_	_
4-15	482-489	through	abstract[23]|abstract[25]	new[23]|giv[25]	_	_
4-16	490-500	industrial	abstract[23]|abstract[25]	new[23]|giv[25]	_	_
4-17	501-508	process	abstract[23]|abstract[25]	new[23]|giv[25]	_	_
4-18	509-514	water	substance|abstract[25]	new|giv[25]	_	_
4-19	515-524	discharge	abstract[25]	giv[25]	_	_
4-20	525-526	.	_	_	_	_

#Text=Several studies have shown that pharmaceutical drugs ( and their derived metabolites ) are found in effluents of wastewater treatment plants ( WWTPs ) and their removal is very inefficient .
5-1	527-534	Several	abstract[26]	new[26]	_	_
5-2	535-542	studies	abstract[26]	new[26]	_	_
5-3	543-547	have	_	_	_	_
5-4	548-553	shown	_	_	_	_
5-5	554-558	that	_	_	_	_
5-6	559-573	pharmaceutical	substance[27]|substance[28]	new[27]|new[28]	ana|coref	5-26[0_28]|6-7[39_27]
5-7	574-579	drugs	substance[27]|substance[28]	new[27]|new[28]	_	_
5-8	580-581	(	substance[28]	new[28]	_	_
5-9	582-585	and	substance[28]	new[28]	_	_
5-10	586-591	their	substance[28]|substance[29]	new[28]|new[29]	_	_
5-11	592-599	derived	substance[28]|substance[29]	new[28]|new[29]	_	_
5-12	600-611	metabolites	substance[28]|substance[29]	new[28]|new[29]	_	_
5-13	612-613	)	substance[28]	new[28]	_	_
5-14	614-617	are	_	_	_	_
5-15	618-623	found	_	_	_	_
5-16	624-626	in	_	_	_	_
5-17	627-636	effluents	person[30]	new[30]	_	_
5-18	637-639	of	person[30]	new[30]	_	_
5-19	640-650	wastewater	person[30]|substance|plant[33]	new[30]|giv|new[33]	coref|coref	6-1|9-14[66_33]
5-20	651-660	treatment	person[30]|event|plant[33]	new[30]|new|new[33]	coref	9-16
5-21	661-667	plants	person[30]|plant[33]	new[30]|new[33]	_	_
5-22	668-669	(	_	_	_	_
5-23	670-675	WWTPs	object	new	_	_
5-24	676-677	)	_	_	_	_
5-25	678-681	and	_	_	_	_
5-26	682-687	their	substance|event[36]	giv|new[36]	coref	15-17[105_36]
5-27	688-695	removal	event[36]	new[36]	_	_
5-28	696-698	is	_	_	_	_
5-29	699-703	very	_	_	_	_
5-30	704-715	inefficient	_	_	_	_
5-31	716-717	.	_	_	_	_

#Text=Wastewater originating during the manufacturing of antidiabetic drugs is also an important environmental challenge due to the high production volume .
6-1	718-728	Wastewater	abstract	giv	coref	6-11[40_0]
6-2	729-740	originating	_	_	_	_
6-3	741-747	during	_	_	_	_
6-4	748-751	the	abstract[38]	giv[38]	_	_
6-5	752-765	manufacturing	abstract[38]	giv[38]	_	_
6-6	766-768	of	abstract[38]	giv[38]	_	_
6-7	769-781	antidiabetic	abstract[38]|substance[39]	giv[38]|giv[39]	coref	7-15[48_39]
6-8	782-787	drugs	abstract[38]|substance[39]	giv[38]|giv[39]	_	_
6-9	788-790	is	_	_	_	_
6-10	791-795	also	_	_	_	_
6-11	796-798	an	abstract[40]	giv[40]	coref	7-18[0_40]
6-12	799-808	important	abstract[40]	giv[40]	_	_
6-13	809-822	environmental	abstract[40]	giv[40]	_	_
6-14	823-832	challenge	abstract[40]	giv[40]	_	_
6-15	833-836	due	abstract[40]	giv[40]	_	_
6-16	837-839	to	_	_	_	_
6-17	840-843	the	quantity[42]	new[42]	_	_
6-18	844-848	high	quantity[42]	new[42]	_	_
6-19	849-859	production	abstract|quantity[42]	new|new[42]	_	_
6-20	860-866	volume	quantity[42]	new[42]	_	_
6-21	867-868	.	_	_	_	_

#Text=Several research papers have reported the occurrence , degradability , and environmental impact of antidiabetic drugs in wastewater , and substantial efforts to achieve environmental improvements in line with regulations and legislation have been implemented .
7-1	869-876	Several	object[44]	new[44]	_	_
7-2	877-885	research	abstract|object[44]	new|new[44]	_	_
7-3	886-892	papers	object[44]	new[44]	_	_
7-4	893-897	have	_	_	_	_
7-5	898-906	reported	_	_	_	_
7-6	907-910	the	abstract[45]	new[45]	_	_
7-7	911-921	occurrence	abstract[45]	new[45]	_	_
7-8	922-923	,	_	_	_	_
7-9	924-937	degradability	abstract	new	_	_
7-10	938-939	,	_	_	_	_
7-11	940-943	and	_	_	_	_
7-12	944-957	environmental	abstract[47]	new[47]	coref	8-6[56_47]
7-13	958-964	impact	abstract[47]	new[47]	_	_
7-14	965-967	of	abstract[47]	new[47]	_	_
7-15	968-980	antidiabetic	abstract[47]|substance[48]	new[47]|giv[48]	coref	8-8[57_48]
7-16	981-986	drugs	abstract[47]|substance[48]	new[47]|giv[48]	_	_
7-17	987-989	in	abstract[47]|substance[48]	new[47]|giv[48]	_	_
7-18	990-1000	wastewater	abstract[47]|substance[48]|substance	new[47]|giv[48]|giv	coref	9-15
7-19	1001-1002	,	_	_	_	_
7-20	1003-1006	and	_	_	_	_
7-21	1007-1018	substantial	event[50]	new[50]	_	_
7-22	1019-1026	efforts	event[50]	new[50]	_	_
7-23	1027-1029	to	_	_	_	_
7-24	1030-1037	achieve	_	_	_	_
7-25	1038-1051	environmental	abstract[51]	new[51]	_	_
7-26	1052-1064	improvements	abstract[51]	new[51]	_	_
7-27	1065-1067	in	abstract[51]	new[51]	_	_
7-28	1068-1072	line	abstract[51]	new[51]	_	_
7-29	1073-1077	with	abstract[51]	new[51]	_	_
7-30	1078-1089	regulations	abstract[51]|abstract	new[51]|new	_	_
7-31	1090-1093	and	abstract[51]	new[51]	_	_
7-32	1094-1105	legislation	abstract[51]|abstract	new[51]|new	_	_
7-33	1106-1110	have	_	_	_	_
7-34	1111-1115	been	_	_	_	_
7-35	1116-1127	implemented	_	_	_	_
7-36	1128-1129	.	_	_	_	_

#Text=Metformin ( C4H11N5 ) is one of the most prescribed and widely used antidiabetic drugs worldwide , since a significant portion of the population suffers from diabetes .
8-1	1130-1139	Metformin	abstract	new	appos	8-3
8-2	1140-1141	(	_	_	_	_
8-3	1142-1149	C4H11N5	abstract	giv	_	_
8-4	1150-1151	)	_	_	_	_
8-5	1152-1154	is	_	_	_	_
8-6	1155-1158	one	abstract[56]	giv[56]	_	_
8-7	1159-1161	of	abstract[56]	giv[56]	_	_
8-8	1162-1165	the	abstract[56]|substance[57]	giv[56]|giv[57]	_	_
8-9	1166-1170	most	abstract[56]|substance[57]	giv[56]|giv[57]	_	_
8-10	1171-1181	prescribed	abstract[56]|substance[57]	giv[56]|giv[57]	_	_
8-11	1182-1185	and	abstract[56]|substance[57]	giv[56]|giv[57]	_	_
8-12	1186-1192	widely	abstract[56]|substance[57]	giv[56]|giv[57]	_	_
8-13	1193-1197	used	abstract[56]|substance[57]	giv[56]|giv[57]	_	_
8-14	1198-1210	antidiabetic	abstract[56]|substance[57]	giv[56]|giv[57]	_	_
8-15	1211-1216	drugs	abstract[56]|substance[57]	giv[56]|giv[57]	_	_
8-16	1217-1226	worldwide	abstract[56]|substance[57]	giv[56]|giv[57]	_	_
8-17	1227-1228	,	_	_	_	_
8-18	1229-1234	since	_	_	_	_
8-19	1235-1236	a	quantity[58]	new[58]	ana	10-4[0_58]
8-20	1237-1248	significant	quantity[58]	new[58]	_	_
8-21	1249-1256	portion	quantity[58]	new[58]	_	_
8-22	1257-1259	of	quantity[58]	new[58]	_	_
8-23	1260-1263	the	quantity[58]|person[59]	new[58]|new[59]	_	_
8-24	1264-1274	population	quantity[58]|person[59]	new[58]|new[59]	_	_
8-25	1275-1282	suffers	_	_	_	_
8-26	1283-1287	from	_	_	_	_
8-27	1288-1296	diabetes	abstract	new	_	_
8-28	1297-1298	.	_	_	_	_

#Text=Recent reports have indicated that there are also high concentrations of metformin in domestic wastewater treatment plants ’ influent .
9-1	1299-1305	Recent	abstract[61]	new[61]	_	_
9-2	1306-1313	reports	abstract[61]	new[61]	_	_
9-3	1314-1318	have	_	_	_	_
9-4	1319-1328	indicated	_	_	_	_
9-5	1329-1333	that	_	_	_	_
9-6	1334-1339	there	_	_	_	_
9-7	1340-1343	are	_	_	_	_
9-8	1344-1348	also	_	_	_	_
9-9	1349-1353	high	abstract[62]	new[62]	_	_
9-10	1354-1368	concentrations	abstract[62]	new[62]	_	_
9-11	1369-1371	of	abstract[62]	new[62]	_	_
9-12	1372-1381	metformin	abstract[62]|substance[63]	new[62]|new[63]	ana	10-1[0_63]
9-13	1382-1384	in	abstract[62]|substance[63]	new[62]|new[63]	_	_
9-14	1385-1393	domestic	abstract[62]|substance[63]|plant[66]|person[67]	new[62]|new[63]|giv[66]|new[67]	coref	14-21[98_66]
9-15	1394-1404	wastewater	abstract[62]|substance[63]|substance|plant[66]|person[67]	new[62]|new[63]|giv|giv[66]|new[67]	coref	10-18
9-16	1405-1414	treatment	abstract[62]|substance[63]|event|plant[66]|person[67]	new[62]|new[63]|giv|giv[66]|new[67]	coref	12-7[84_0]
9-17	1415-1421	plants	abstract[62]|substance[63]|plant[66]|person[67]	new[62]|new[63]|giv[66]|new[67]	_	_
9-18	1422-1423	’	abstract[62]|substance[63]|plant[66]|person[67]	new[62]|new[63]|giv[66]|new[67]	_	_
9-19	1424-1432	influent	abstract[62]|substance[63]|person[67]	new[62]|new[63]|new[67]	_	_
9-20	1433-1434	.	_	_	_	_

#Text=This is because it is excreted un-metabolized from the human body in urine and ends up in wastewater and aquatic environments .
10-1	1435-1439	This	substance	giv	coref	11-1
10-2	1440-1442	is	_	_	_	_
10-3	1443-1450	because	_	_	_	_
10-4	1451-1453	it	quantity	giv	_	_
10-5	1454-1456	is	_	_	_	_
10-6	1457-1465	excreted	_	_	_	_
10-7	1466-1480	un-metabolized	_	_	_	_
10-8	1481-1485	from	_	_	_	_
10-9	1486-1489	the	object[70]	new[70]	_	_
10-10	1490-1495	human	object[70]	new[70]	_	_
10-11	1496-1500	body	object[70]	new[70]	_	_
10-12	1501-1503	in	object[70]	new[70]	_	_
10-13	1504-1509	urine	object[70]|substance	new[70]|new	_	_
10-14	1510-1513	and	_	_	_	_
10-15	1514-1518	ends	_	_	_	_
10-16	1519-1521	up	_	_	_	_
10-17	1522-1524	in	_	_	_	_
10-18	1525-1535	wastewater	substance|substance[73]	giv|giv[73]	coref	11-11[78_0]
10-19	1536-1539	and	substance[73]	giv[73]	_	_
10-20	1540-1547	aquatic	substance[73]|place[74]	giv[73]|new[74]	_	_
10-21	1548-1560	environments	substance[73]|place[74]	giv[73]|new[74]	_	_
10-22	1561-1562	.	_	_	_	_

#Text=Metformin is the pharmaceutical compound with the highest concentration in domestic wastewater ( i. e. , 64 – 98 µg/L ) .
11-1	1563-1572	Metformin	substance	giv	coref	11-3[76_0]
11-2	1573-1575	is	_	_	_	_
11-3	1576-1579	the	substance[76]	giv[76]	coref	14-1[0_76]
11-4	1580-1594	pharmaceutical	substance[76]	giv[76]	_	_
11-5	1595-1603	compound	substance[76]	giv[76]	_	_
11-6	1604-1608	with	substance[76]	giv[76]	_	_
11-7	1609-1612	the	substance[76]|abstract[77]	giv[76]|new[77]	_	_
11-8	1613-1620	highest	substance[76]|abstract[77]	giv[76]|new[77]	_	_
11-9	1621-1634	concentration	substance[76]|abstract[77]	giv[76]|new[77]	_	_
11-10	1635-1637	in	substance[76]|abstract[77]	giv[76]|new[77]	_	_
11-11	1638-1646	domestic	substance[76]|abstract[77]|substance[78]	giv[76]|new[77]|giv[78]	coref	12-7[0_78]
11-12	1647-1657	wastewater	substance[76]|abstract[77]|substance[78]	giv[76]|new[77]|giv[78]	_	_
11-13	1658-1659	(	_	_	_	_
11-14	1660-1662	i.	_	_	_	_
11-15	1663-1665	e.	_	_	_	_
11-16	1666-1667	,	_	_	_	_
11-17	1668-1670	64	quantity[79]	new[79]	_	_
11-18	1671-1672	–	quantity[79]	new[79]	_	_
11-19	1673-1675	98	quantity[79]|quantity	new[79]|new	_	_
11-20	1676-1680	µg/L	quantity[79]|quantity	new[79]|new	_	_
11-21	1681-1682	)	_	_	_	_
11-22	1683-1684	.	_	_	_	_

#Text=This study is therefore relevant for wastewater treatment in general , even though it is focused on metformin-containing industrial wastewater .
12-1	1685-1689	This	abstract[82]	new[82]	coref	16-5[109_82]
12-2	1690-1695	study	abstract[82]	new[82]	_	_
12-3	1696-1698	is	_	_	_	_
12-4	1699-1708	therefore	_	_	_	_
12-5	1709-1717	relevant	_	_	_	_
12-6	1718-1721	for	_	_	_	_
12-7	1722-1732	wastewater	substance|event[84]	giv|giv[84]	ana|coref	12-14[0_84]|12-18[87_0]
12-8	1733-1742	treatment	event[84]	giv[84]	_	_
12-9	1743-1745	in	_	_	_	_
12-10	1746-1753	general	person	new	_	_
12-11	1754-1755	,	_	_	_	_
12-12	1756-1760	even	_	_	_	_
12-13	1761-1767	though	_	_	_	_
12-14	1768-1770	it	event	giv	coref	14-22
12-15	1771-1773	is	_	_	_	_
12-16	1774-1781	focused	_	_	_	_
12-17	1782-1784	on	_	_	_	_
12-18	1785-1805	metformin-containing	substance[87]	giv[87]	coref	13-1[88_87]
12-19	1806-1816	industrial	substance[87]	giv[87]	_	_
12-20	1817-1827	wastewater	substance[87]	giv[87]	_	_
12-21	1828-1829	.	_	_	_	_

#Text=Pharmaceutical wastewater has traditionally been treated using conventional physico-chemical and biological process methods .
13-1	1830-1844	Pharmaceutical	substance[88]	giv[88]	coref	14-21[0_88]
13-2	1845-1855	wastewater	substance[88]	giv[88]	_	_
13-3	1856-1859	has	_	_	_	_
13-4	1860-1873	traditionally	_	_	_	_
13-5	1874-1878	been	_	_	_	_
13-6	1879-1886	treated	_	_	_	_
13-7	1887-1892	using	_	_	_	_
13-8	1893-1905	conventional	abstract[90]	new[90]	_	_
13-9	1906-1922	physico-chemical	abstract[90]	new[90]	_	_
13-10	1923-1926	and	abstract[90]	new[90]	_	_
13-11	1927-1937	biological	abstract[90]	new[90]	_	_
13-12	1938-1945	process	abstract|abstract[90]	giv|new[90]	coref	21-1[144_0]
13-13	1946-1953	methods	abstract[90]	new[90]	_	_
13-14	1954-1955	.	_	_	_	_

#Text=Metformin can be aerobically degraded to guanylurea ( C2H6N4O ) — a metabolite that is stable against further biodegradation in wastewater treatment plants .
14-1	1956-1965	Metformin	substance	giv	coref	15-21
14-2	1966-1969	can	_	_	_	_
14-3	1970-1972	be	_	_	_	_
14-4	1973-1984	aerobically	_	_	_	_
14-5	1985-1993	degraded	_	_	_	_
14-6	1994-1996	to	_	_	_	_
14-7	1997-2007	guanylurea	substance	new	appos	14-9
14-8	2008-2009	(	_	_	_	_
14-9	2010-2017	C2H6N4O	substance	giv	_	_
14-10	2018-2019	)	_	_	_	_
14-11	2020-2021	—	_	_	_	_
14-12	2022-2023	a	object[94]	new[94]	ana	15-3[0_94]
14-13	2024-2034	metabolite	object[94]	new[94]	_	_
14-14	2035-2039	that	_	_	_	_
14-15	2040-2042	is	_	_	_	_
14-16	2043-2049	stable	_	_	_	_
14-17	2050-2057	against	_	_	_	_
14-18	2058-2065	further	substance[95]	new[95]	_	_
14-19	2066-2080	biodegradation	substance[95]	new[95]	_	_
14-20	2081-2083	in	substance[95]	new[95]	_	_
14-21	2084-2094	wastewater	substance[95]|substance|plant[98]	new[95]|giv|giv[98]	coref	23-1
14-22	2095-2104	treatment	substance[95]|event|plant[98]	new[95]|giv|giv[98]	coref	24-8[162_0]
14-23	2105-2111	plants	substance[95]|plant[98]	new[95]|giv[98]	_	_
14-24	2112-2113	.	_	_	_	_

#Text=However , it appears to be a novel idea to integrate anaerobic and aerobic processes for the efficient removal of metformin and other pharmaceutical constituents .
15-1	2114-2121	However	_	_	_	_
15-2	2122-2123	,	_	_	_	_
15-3	2124-2126	it	object	giv	_	_
15-4	2127-2134	appears	_	_	_	_
15-5	2135-2137	to	_	_	_	_
15-6	2138-2140	be	_	_	_	_
15-7	2141-2142	a	abstract[100]	new[100]	_	_
15-8	2143-2148	novel	abstract[100]	new[100]	_	_
15-9	2149-2153	idea	abstract[100]	new[100]	_	_
15-10	2154-2156	to	_	_	_	_
15-11	2157-2166	integrate	_	_	_	_
15-12	2167-2176	anaerobic	substance|abstract[102]	new|new[102]	coref|coref	16-9|22-8[152_102]
15-13	2177-2180	and	abstract[102]	new[102]	_	_
15-14	2181-2188	aerobic	abstract[102]|abstract|abstract[104]	new[102]|new|giv[104]	coref|coref	16-13|22-11[153_104]
15-15	2189-2198	processes	abstract[102]|abstract[104]	new[102]|giv[104]	_	_
15-16	2199-2202	for	_	_	_	_
15-17	2203-2206	the	event[105]	giv[105]	coref	28-45[0_105]
15-18	2207-2216	efficient	event[105]	giv[105]	_	_
15-19	2217-2224	removal	event[105]	giv[105]	_	_
15-20	2225-2227	of	event[105]	giv[105]	_	_
15-21	2228-2237	metformin	event[105]|substance	giv[105]|giv	coref	28-36
15-22	2238-2241	and	event[105]	giv[105]	_	_
15-23	2242-2247	other	event[105]|substance[107]	giv[105]|new[107]	coref	21-6[145_107]
15-24	2248-2262	pharmaceutical	event[105]|substance[107]	giv[105]|new[107]	_	_
15-25	2263-2275	constituents	event[105]|substance[107]	giv[105]|new[107]	_	_
15-26	2276-2277	.	_	_	_	_

#Text=The basic hypothesis of this study is that anaerobic granular sludge and aerobic biofilms supported by a hybrid vertical anaerobic biofilm ( HyVAB® ) reactor design (
16-1	2278-2281	The	abstract[108]	new[108]	_	_
16-2	2282-2287	basic	abstract[108]	new[108]	_	_
16-3	2288-2298	hypothesis	abstract[108]	new[108]	_	_
16-4	2299-2301	of	abstract[108]	new[108]	_	_
16-5	2302-2306	this	abstract[108]|abstract[109]	new[108]|giv[109]	coref	28-2[187_109]
16-6	2307-2312	study	abstract[108]|abstract[109]	new[108]|giv[109]	_	_
16-7	2313-2315	is	_	_	_	_
16-8	2316-2320	that	_	_	_	_
16-9	2321-2330	anaerobic	abstract|substance[111]	giv|new[111]	coref	16-20
16-10	2331-2339	granular	substance[111]	new[111]	_	_
16-11	2340-2346	sludge	substance[111]	new[111]	_	_
16-12	2347-2350	and	_	_	_	_
16-13	2351-2358	aerobic	abstract|substance[113]	giv|new[113]	coref	26-2
16-14	2359-2367	biofilms	substance[113]	new[113]	_	_
16-15	2368-2377	supported	_	_	_	_
16-16	2378-2380	by	_	_	_	_
16-17	2381-2382	a	abstract[115]	new[115]	appos	16-23[0_115]
16-18	2383-2389	hybrid	abstract[115]	new[115]	_	_
16-19	2390-2398	vertical	abstract[115]	new[115]	_	_
16-20	2399-2408	anaerobic	abstract|abstract[115]	giv|new[115]	coref	22-8[151_0]
16-21	2409-2416	biofilm	abstract[115]	new[115]	_	_
16-22	2417-2418	(	_	_	_	_
16-23	2419-2425	HyVAB®	abstract	giv	coref	22-1
16-24	2426-2427	)	_	_	_	_
16-25	2428-2435	reactor	person|abstract[118]	new|new[118]	_	_
16-26	2436-2442	design	abstract[118]	new[118]	_	_
16-27	2443-2444	(	_	_	_	_

#Text=Figure 1
17-1	2445-2451	Figure	object[119]	new[119]	_	_
17-2	2452-2453	1	object[119]	new[119]	_	_

#Text=) are the most robust combined niches for microorganisms to treat inhibitory substances , since microbial aggregates protect the microorganisms against such substances as they are delivered slowly by diffusion from the liquid phase .
18-1	2454-2455	)	_	_	_	_
18-2	2456-2459	are	_	_	_	_
18-3	2460-2463	the	abstract[120]	new[120]	ana	18-25[0_120]
18-4	2464-2468	most	abstract[120]	new[120]	_	_
18-5	2469-2475	robust	abstract[120]	new[120]	_	_
18-6	2476-2484	combined	abstract[120]	new[120]	_	_
18-7	2485-2491	niches	abstract[120]	new[120]	_	_
18-8	2492-2495	for	abstract[120]	new[120]	_	_
18-9	2496-2510	microorganisms	abstract[120]|animal	new[120]|new	coref	18-19[124_0]
18-10	2511-2513	to	_	_	_	_
18-11	2514-2519	treat	_	_	_	_
18-12	2520-2530	inhibitory	substance[122]	new[122]	coref	18-22[125_122]
18-13	2531-2541	substances	substance[122]	new[122]	_	_
18-14	2542-2543	,	_	_	_	_
18-15	2544-2549	since	_	_	_	_
18-16	2550-2559	microbial	object[123]	new[123]	coref	21-16[148_123]
18-17	2560-2570	aggregates	object[123]	new[123]	_	_
18-18	2571-2578	protect	_	_	_	_
18-19	2579-2582	the	animal[124]	giv[124]	_	_
18-20	2583-2597	microorganisms	animal[124]	giv[124]	_	_
18-21	2598-2605	against	animal[124]	giv[124]	_	_
18-22	2606-2610	such	animal[124]|substance[125]	giv[124]|giv[125]	_	_
18-23	2611-2621	substances	animal[124]|substance[125]	giv[124]|giv[125]	_	_
18-24	2622-2624	as	_	_	_	_
18-25	2625-2629	they	abstract	giv	_	_
18-26	2630-2633	are	_	_	_	_
18-27	2634-2643	delivered	_	_	_	_
18-28	2644-2650	slowly	_	_	_	_
18-29	2651-2653	by	_	_	_	_
18-30	2654-2663	diffusion	abstract[127]	new[127]	_	_
18-31	2664-2668	from	abstract[127]	new[127]	_	_
18-32	2669-2672	the	abstract[127]|abstract[129]	new[127]|new[129]	coref	20-28[142_129]
18-33	2673-2679	liquid	abstract[127]|substance|abstract[129]	new[127]|new|new[129]	_	_
18-34	2680-2685	phase	abstract[127]|abstract[129]	new[127]|new[129]	_	_
18-35	2686-2687	.	_	_	_	_

#Text=The more sensitive organisms are in the deeper layers protected by layers of organisms embedded in an extracellular polymeric matrix .
19-1	2688-2691	The	animal[130]	new[130]	coref	19-14[0_130]
19-2	2692-2696	more	animal[130]	new[130]	_	_
19-3	2697-2706	sensitive	animal[130]	new[130]	_	_
19-4	2707-2716	organisms	animal[130]	new[130]	_	_
19-5	2717-2720	are	_	_	_	_
19-6	2721-2723	in	_	_	_	_
19-7	2724-2727	the	abstract[131]	new[131]	coref	19-12[132_131]
19-8	2728-2734	deeper	abstract[131]	new[131]	_	_
19-9	2735-2741	layers	abstract[131]	new[131]	_	_
19-10	2742-2751	protected	_	_	_	_
19-11	2752-2754	by	_	_	_	_
19-12	2755-2761	layers	abstract[132]	giv[132]	_	_
19-13	2762-2764	of	abstract[132]	giv[132]	_	_
19-14	2765-2774	organisms	abstract[132]|animal	giv[132]|giv	_	_
19-15	2775-2783	embedded	_	_	_	_
19-16	2784-2786	in	_	_	_	_
19-17	2787-2789	an	substance[134]	new[134]	coref	21-11[147_134]
19-18	2790-2803	extracellular	substance[134]	new[134]	_	_
19-19	2804-2813	polymeric	substance[134]	new[134]	_	_
19-20	2814-2820	matrix	substance[134]	new[134]	_	_
19-21	2821-2822	.	_	_	_	_

#Text=Adaptation to toxic chemicals can be slow and can go through the stages of survival , tolerance , capture , and — if at all biodegradable — the final adaptation stage is degradation .
20-1	2823-2833	Adaptation	abstract[135]	new[135]	coref	20-30[0_135]
20-2	2834-2836	to	abstract[135]	new[135]	_	_
20-3	2837-2842	toxic	abstract[135]|substance[136]	new[135]|new[136]	_	_
20-4	2843-2852	chemicals	abstract[135]|substance[136]	new[135]|new[136]	_	_
20-5	2853-2856	can	_	_	_	_
20-6	2857-2859	be	_	_	_	_
20-7	2860-2864	slow	_	_	_	_
20-8	2865-2868	and	_	_	_	_
20-9	2869-2872	can	_	_	_	_
20-10	2873-2875	go	_	_	_	_
20-11	2876-2883	through	_	_	_	_
20-12	2884-2887	the	abstract[137]	new[137]	_	_
20-13	2888-2894	stages	abstract[137]	new[137]	_	_
20-14	2895-2897	of	abstract[137]	new[137]	_	_
20-15	2898-2906	survival	abstract[137]|event	new[137]|new	_	_
20-16	2907-2908	,	abstract[137]	new[137]	_	_
20-17	2909-2918	tolerance	abstract[137]|abstract	new[137]|new	_	_
20-18	2919-2920	,	abstract[137]	new[137]	_	_
20-19	2921-2928	capture	abstract[137]|event	new[137]|new	_	_
20-20	2929-2930	,	_	_	_	_
20-21	2931-2934	and	_	_	_	_
20-22	2935-2936	—	_	_	_	_
20-23	2937-2939	if	_	_	_	_
20-24	2940-2942	at	_	_	_	_
20-25	2943-2946	all	_	_	_	_
20-26	2947-2960	biodegradable	_	_	_	_
20-27	2961-2962	—	_	_	_	_
20-28	2963-2966	the	abstract[142]	giv[142]	coref	20-33[0_142]
20-29	2967-2972	final	abstract[142]	giv[142]	_	_
20-30	2973-2983	adaptation	abstract|abstract[142]	giv|giv[142]	_	_
20-31	2984-2989	stage	abstract[142]	giv[142]	_	_
20-32	2990-2992	is	_	_	_	_
20-33	2993-3004	degradation	abstract	giv	coref	23-12
20-34	3005-3006	.	_	_	_	_

#Text=The process can even remove non-biodegradable constituents by integration in the extracellular matrix to build more aggregates .
21-1	3007-3010	The	abstract[144]	giv[144]	coref	26-8[177_144]
21-2	3011-3018	process	abstract[144]	giv[144]	_	_
21-3	3019-3022	can	_	_	_	_
21-4	3023-3027	even	_	_	_	_
21-5	3028-3034	remove	_	_	_	_
21-6	3035-3052	non-biodegradable	substance[145]	giv[145]	_	_
21-7	3053-3065	constituents	substance[145]	giv[145]	_	_
21-8	3066-3068	by	_	_	_	_
21-9	3069-3080	integration	abstract[146]	new[146]	_	_
21-10	3081-3083	in	abstract[146]	new[146]	_	_
21-11	3084-3087	the	abstract[146]|substance[147]	new[146]|giv[147]	_	_
21-12	3088-3101	extracellular	abstract[146]|substance[147]	new[146]|giv[147]	_	_
21-13	3102-3108	matrix	abstract[146]|substance[147]	new[146]|giv[147]	_	_
21-14	3109-3111	to	_	_	_	_
21-15	3112-3117	build	_	_	_	_
21-16	3118-3122	more	object[148]	giv[148]	_	_
21-17	3123-3133	aggregates	object[148]	giv[148]	_	_
21-18	3134-3135	.	_	_	_	_

#Text=HyVAB® is a compact reactor that integrates both anaerobic and aerobic processes .
22-1	3136-3142	HyVAB®	abstract	giv	coref	22-3[150_0]
22-2	3143-3145	is	_	_	_	_
22-3	3146-3147	a	object[150]	giv[150]	coref	24-13[0_150]
22-4	3148-3155	compact	object[150]	giv[150]	_	_
22-5	3156-3163	reactor	object[150]	giv[150]	_	_
22-6	3164-3168	that	_	_	_	_
22-7	3169-3179	integrates	_	_	_	_
22-8	3180-3184	both	substance[151]|abstract[152]	giv[151]|giv[152]	coref	23-7[0_151]
22-9	3185-3194	anaerobic	substance[151]|abstract[152]	giv[151]|giv[152]	_	_
22-10	3195-3198	and	abstract[152]	giv[152]	_	_
22-11	3199-3206	aerobic	abstract[152]|abstract[153]	giv[152]|giv[153]	_	_
22-12	3207-3216	processes	abstract[152]|abstract[153]	giv[152]|giv[153]	_	_
22-13	3217-3218	.	_	_	_	_

#Text=Wastewater is introduced at the bottom anaerobic digestion ( AD ) stage , where organic matter is degraded and converted into methane .
23-1	3219-3229	Wastewater	substance	giv	coref	28-8
23-2	3230-3232	is	_	_	_	_
23-3	3233-3243	introduced	_	_	_	_
23-4	3244-3246	at	_	_	_	_
23-5	3247-3250	the	abstract[156]	new[156]	appos	23-10[0_156]
23-6	3251-3257	bottom	abstract[156]	new[156]	_	_
23-7	3258-3267	anaerobic	substance|abstract[156]	giv|new[156]	_	_
23-8	3268-3277	digestion	abstract[156]	new[156]	_	_
23-9	3278-3279	(	_	_	_	_
23-10	3280-3282	AD	abstract	giv	coref	27-13
23-11	3283-3284	)	_	_	_	_
23-12	3285-3290	stage	abstract	giv	coref	24-11[164_0]
23-13	3291-3292	,	_	_	_	_
23-14	3293-3298	where	_	_	_	_
23-15	3299-3306	organic	substance[159]	new[159]	_	_
23-16	3307-3313	matter	substance[159]	new[159]	_	_
23-17	3314-3316	is	_	_	_	_
23-18	3317-3325	degraded	_	_	_	_
23-19	3326-3329	and	_	_	_	_
23-20	3330-3339	converted	_	_	_	_
23-21	3340-3344	into	_	_	_	_
23-22	3345-3352	methane	substance	new	_	_
23-23	3353-3354	.	_	_	_	_

#Text=The remaining unconsumed organics flow up for further treatment in the aerobic biofilm stage designed as a Continuous Flow Intermittent Cleaning ( CFIC® ) .
24-1	3355-3358	The	substance[161]	new[161]	_	_
24-2	3359-3368	remaining	substance[161]	new[161]	_	_
24-3	3369-3379	unconsumed	substance[161]	new[161]	_	_
24-4	3380-3388	organics	substance[161]	new[161]	_	_
24-5	3389-3393	flow	_	_	_	_
24-6	3394-3396	up	_	_	_	_
24-7	3397-3400	for	_	_	_	_
24-8	3401-3408	further	event[162]	giv[162]	_	_
24-9	3409-3418	treatment	event[162]	giv[162]	_	_
24-10	3419-3421	in	event[162]	giv[162]	_	_
24-11	3422-3425	the	event[162]|abstract[164]	giv[162]|giv[164]	coref	25-9[171_164]
24-12	3426-3433	aerobic	event[162]|abstract[164]	giv[162]|giv[164]	_	_
24-13	3434-3441	biofilm	event[162]|abstract|abstract[164]	giv[162]|giv|giv[164]	coref	25-6
24-14	3442-3447	stage	event[162]|abstract[164]	giv[162]|giv[164]	_	_
24-15	3448-3456	designed	_	_	_	_
24-16	3457-3459	as	_	_	_	_
24-17	3460-3461	a	_	_	_	_
24-18	3462-3472	Continuous	_	_	_	_
24-19	3473-3477	Flow	abstract	new	_	_
24-20	3478-3490	Intermittent	organization	new	_	_
24-21	3491-3499	Cleaning	_	_	_	_
24-22	3500-3501	(	_	_	_	_
24-23	3502-3507	CFIC®	abstract	new	coref	26-16
24-24	3508-3509	)	_	_	_	_
24-25	3510-3511	.	_	_	_	_

#Text=Plastic bio-carriers serve as a biofilm substratum in the aerobic biofilm stage , protecting the biofilm from shear force .
25-1	3512-3519	Plastic	object[168]	new[168]	_	_
25-2	3520-3532	bio-carriers	object[168]	new[168]	_	_
25-3	3533-3538	serve	_	_	_	_
25-4	3539-3541	as	_	_	_	_
25-5	3542-3543	a	_	_	_	_
25-6	3544-3551	biofilm	abstract	giv	coref	25-11
25-7	3552-3562	substratum	_	_	_	_
25-8	3563-3565	in	_	_	_	_
25-9	3566-3569	the	abstract[171]	giv[171]	coref	27-12[182_171]
25-10	3570-3577	aerobic	abstract[171]	giv[171]	_	_
25-11	3578-3585	biofilm	abstract|abstract[171]	giv|giv[171]	coref	25-15[172_0]
25-12	3586-3591	stage	abstract[171]	giv[171]	_	_
25-13	3592-3593	,	_	_	_	_
25-14	3594-3604	protecting	_	_	_	_
25-15	3605-3608	the	abstract[172]	giv[172]	coref	27-16[183_172]
25-16	3609-3616	biofilm	abstract[172]	giv[172]	_	_
25-17	3617-3621	from	_	_	_	_
25-18	3622-3627	shear	abstract[173]	new[173]	_	_
25-19	3628-3633	force	abstract[173]	new[173]	_	_
25-20	3634-3635	.	_	_	_	_

#Text=Excess aerobic sludge is washed off during the intermittent washing process ( i. e. , CFIC® ) .
26-1	3636-3642	Excess	substance[175]	new[175]	_	_
26-2	3643-3650	aerobic	abstract|substance[175]	giv|new[175]	_	_
26-3	3651-3657	sludge	substance[175]	new[175]	_	_
26-4	3658-3660	is	_	_	_	_
26-5	3661-3667	washed	_	_	_	_
26-6	3668-3671	off	_	_	_	_
26-7	3672-3678	during	_	_	_	_
26-8	3679-3682	the	abstract[177]	giv[177]	_	_
26-9	3683-3695	intermittent	abstract[177]	giv[177]	_	_
26-10	3696-3703	washing	abstract|abstract[177]	new|giv[177]	_	_
26-11	3704-3711	process	abstract[177]	giv[177]	_	_
26-12	3712-3713	(	_	_	_	_
26-13	3714-3716	i.	_	_	_	_
26-14	3717-3719	e.	_	_	_	_
26-15	3720-3721	,	_	_	_	_
26-16	3722-3727	CFIC®	abstract	giv	_	_
26-17	3728-3729	)	_	_	_	_
26-18	3730-3731	.	_	_	_	_

#Text=Part of the detached aerobic biofilm settles down by gravity to the AD stage in the HyVAB® , where it is degraded simultaneously with the feed substrates .
27-1	3732-3736	Part	_	_	_	_
27-2	3737-3739	of	_	_	_	_
27-3	3740-3743	the	substance[179]	new[179]	ana	27-20[0_179]
27-4	3744-3752	detached	substance[179]	new[179]	_	_
27-5	3753-3760	aerobic	substance[179]	new[179]	_	_
27-6	3761-3768	biofilm	substance[179]	new[179]	_	_
27-7	3769-3776	settles	_	_	_	_
27-8	3777-3781	down	_	_	_	_
27-9	3782-3784	by	_	_	_	_
27-10	3785-3792	gravity	abstract	new	_	_
27-11	3793-3795	to	_	_	_	_
27-12	3796-3799	the	abstract[182]	giv[182]	_	_
27-13	3800-3802	AD	abstract|abstract[182]	giv|giv[182]	_	_
27-14	3803-3808	stage	abstract[182]	giv[182]	_	_
27-15	3809-3811	in	abstract[182]	giv[182]	_	_
27-16	3812-3815	the	abstract[182]|abstract[183]	giv[182]|giv[183]	coref	28-25[195_183]
27-17	3816-3822	HyVAB®	abstract[182]|abstract[183]	giv[182]|giv[183]	_	_
27-18	3823-3824	,	_	_	_	_
27-19	3825-3830	where	_	_	_	_
27-20	3831-3833	it	substance	giv	_	_
27-21	3834-3836	is	_	_	_	_
27-22	3837-3845	degraded	_	_	_	_
27-23	3846-3860	simultaneously	_	_	_	_
27-24	3861-3865	with	_	_	_	_
27-25	3866-3869	the	object[186]	new[186]	_	_
27-26	3870-3874	feed	substance|object[186]	new|new[186]	_	_
27-27	3875-3885	substrates	object[186]	new[186]	_	_
27-28	3886-3887	.	_	_	_	_

#Text=In this study , two types of wastewater — wastewater I ( WWI ) and wastewater II ( WWII ) — were fed to the reactor , and performance was evaluated on the basis of metformin reduction , chemical oxygen demand ( COD ) removal efficiency , and biogas production .
28-1	3888-3890	In	_	_	_	_
28-2	3891-3895	this	event[187]	giv[187]	_	_
28-3	3896-3901	study	event[187]	giv[187]	_	_
28-4	3902-3903	,	_	_	_	_
28-5	3904-3907	two	place[188]	new[188]	_	_
28-6	3908-3913	types	place[188]	new[188]	_	_
28-7	3914-3916	of	place[188]	new[188]	_	_
28-8	3917-3927	wastewater	place[188]|substance	new[188]|giv	coref	28-10
28-9	3928-3929	—	_	_	_	_
28-10	3930-3940	wastewater	substance|abstract[191]	giv|new[191]	coref	28-16[193_0]
28-11	3941-3942	I	abstract[191]	new[191]	_	_
28-12	3943-3944	(	_	_	_	_
28-13	3945-3948	WWI	event	new	_	_
28-14	3949-3950	)	_	_	_	_
28-15	3951-3954	and	_	_	_	_
28-16	3955-3965	wastewater	substance[193]	giv[193]	_	_
28-17	3966-3968	II	substance[193]	giv[193]	_	_
28-18	3969-3970	(	_	_	_	_
28-19	3971-3975	WWII	event	new	_	_
28-20	3976-3977	)	_	_	_	_
28-21	3978-3979	—	_	_	_	_
28-22	3980-3984	were	_	_	_	_
28-23	3985-3988	fed	_	_	_	_
28-24	3989-3991	to	_	_	_	_
28-25	3992-3995	the	object[195]	giv[195]	_	_
28-26	3996-4003	reactor	object[195]	giv[195]	_	_
28-27	4004-4005	,	_	_	_	_
28-28	4006-4009	and	_	_	_	_
28-29	4010-4021	performance	abstract	new	_	_
28-30	4022-4025	was	_	_	_	_
28-31	4026-4035	evaluated	_	_	_	_
28-32	4036-4038	on	_	_	_	_
28-33	4039-4042	the	abstract[197]	new[197]	_	_
28-34	4043-4048	basis	abstract[197]	new[197]	_	_
28-35	4049-4051	of	abstract[197]	new[197]	_	_
28-36	4052-4061	metformin	abstract[197]|substance|abstract[199]	new[197]|giv|new[199]	_	_
28-37	4062-4071	reduction	abstract[197]|abstract[199]	new[197]|new[199]	_	_
28-38	4072-4073	,	abstract[197]	new[197]	_	_
28-39	4074-4082	chemical	abstract[197]|abstract[201]	new[197]|new[201]	_	_
28-40	4083-4089	oxygen	abstract[197]|substance|abstract[201]	new[197]|new|new[201]	_	_
28-41	4090-4096	demand	abstract[197]|abstract[201]	new[197]|new[201]	_	_
28-42	4097-4098	(	abstract[197]|abstract[204]	new[197]|new[204]	_	_
28-43	4099-4102	COD	abstract[197]|substance|abstract[204]	new[197]|new|new[204]	_	_
28-44	4103-4104	)	abstract[197]|abstract[204]	new[197]|new[204]	_	_
28-45	4105-4112	removal	abstract[197]|event|abstract[204]	new[197]|giv|new[204]	_	_
28-46	4113-4123	efficiency	abstract[197]|abstract[204]	new[197]|new[204]	_	_
28-47	4124-4125	,	abstract[197]	new[197]	_	_
28-48	4126-4129	and	abstract[197]	new[197]	_	_
28-49	4130-4136	biogas	abstract[197]|substance|abstract[206]	new[197]|new|new[206]	_	_
28-50	4137-4147	production	abstract[197]|abstract[206]	new[197]|new[206]	_	_
28-51	4148-4149	.	_	_	_	_
